EUVIMEDEUVIMED entdecken
Crossref

Endophilin A2, a Potential Therapeutic Target for Lupus, Promotes Lupus Progression

Lu-Qi Yang, You-Yu Lan, You-Qiang Wang, Si-Yu Feng, An-Fang Huang iD, Wang-Dong Xu iD

International Journal of Rheumatic Diseases · 2025

DOI: 10.1111/1756-185x.70343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Lu-Qi Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, Luzhou, Sichuan, China. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Natural Science Foundation of Sichuan Province, the Science and Technology Strategic Cooperation Programs of Luzhou Municipal People's Government and Southwest Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Endophilin A2 (EPA2) is a member of the Endophilin family. The relationship between EPA2 and SLE pathogenesis is unclear.

Methods

Plasma levels of EPA2 in SLE patients and healthy controls were detected by ELISA, and EPA2 mRNA levels of SLE patients were explored by qRT‐PCR. EPA2 siRNA adenovirus was further injected into pristane‐induced lupus mice, and the histological and serological changes were observed. In vitro, EPA2 siRNA adenovirus was transfected to human umbilical vein endothelial cells (HUVECs) in the presence of growth differentiation factor 15 (GDF15), and the proliferation, migration, and tube‐forming ability of HUVECs were discussed.

Results

Plasma EPA2 levels were significantly higher in SLE patients than in healthy controls ( p < 0.001), and EPA2 mRNA levels were significantly higher in SLE patients than in healthy controls as well ( p = 0.030). Lupus mice exhibited splenomegaly, severe histologic damage, and high levels of autoantibodies (antinuclear antibody (ANA), anti‐double‐stranded DNA antibody (anti‐dsDNA), and immunoglobulin G (IgG)) (vs. the control group, all p < 0.05). After injection of EPA2 siRNA adenoviruses, the lupus mice showed a lower proportion of CD11b + LY‐6C + , F4/80 + , CD11c + , CD19 + , CD8 + , Th1 + , Th2 + , Th17 + cells and reduced expression of pro‐inflammatory cytokines, and autoantibodies (vs. the adenoviral empty vector group, all p < 0.05). Addition of EPA2 siRNA adenovirus to HUVECs resulted in decreased GDF15 mRNA levels and reduced cell proliferation, migration and tube formation. However, in the presence of GDF15, EPA2‐mediated effects were reversed, and the proliferation, migration, and tube formation ability of HUVECs were enhanced.

Conclusion

EPA2 may regulate angiogenesis through GDF15, and then involve in SLE pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicHumansAnimalsHuman Umbilical Vein Endothelial CellsFemaleCase-Control StudiesDisease Models, AnimalCell ProliferationDisease ProgressionAdultMaleCell MovementGrowth Differentiation Factor 15Neovascularization, PhysiologicYoung AdultMiddle AgedMiceSignal TransductionTransfection

Stichwörter der Autor:innen

GDF15HUVECautoimmunityendophilin A2systemic lupus erythematosus

Substanzen

Growth Differentiation Factor 15GDF15 protein, human

Autor:innen und Institutionen

  • Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, Luzhou, Sichuan, China.
  • Department of Rheumatology and Immunology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
  • Department of Laboratory Medicine, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China.

ORCID-Profile: An-Fang Huang, Wang-Dong Xu

Förderung

  • Natural Science Foundation of Sichuan Province
  • the Science and Technology Strategic Cooperation Programs of Luzhou Municipal People's Government and Southwest Medical University

Zitieren

APA

Yang, L. Q., Lan, Y. Y., Wang, Y. Q., Feng, S. Y., Huang, A. F., & Xu, W. D. (2025). Endophilin A2, a Potential Therapeutic Target for Lupus, Promotes Lupus Progression. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70343

Vancouver

Yang LQ, Lan YY, Wang YQ, Feng SY, Huang AF, Xu WD. Endophilin A2, a Potential Therapeutic Target for Lupus, Promotes Lupus Progression. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70343

BibTeX
@article{Yang2025,
  author = {Yang, Lu-Qi and Lan, You-Yu and Wang, You-Qiang and Feng, Si-Yu and Huang, An-Fang and Xu, Wang-Dong},
  title = {Endophilin A2, a Potential Therapeutic Target for Lupus, Promotes Lupus Progression},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  doi = {10.1111/1756-185x.70343}
}
Kostenlos starten →